CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 26 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2014. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,483,675 | +79.1% | 555,610 | 0.0% | 1.29% | +108.4% |
| Q3 2022 | $1,945,000 | +18.7% | 555,610 | 0.0% | 0.62% | +0.3% |
| Q2 2022 | $1,639,000 | -6.3% | 555,610 | -1.2% | 0.62% | +6.4% |
| Q1 2022 | $1,749,000 | -8.0% | 562,339 | 0.0% | 0.58% | +1.0% |
| Q4 2021 | $1,901,000 | -7.4% | 562,339 | 0.0% | 0.57% | -12.4% |
| Q3 2021 | $2,053,000 | -16.3% | 562,339 | 0.0% | 0.65% | +7.2% |
| Q2 2021 | $2,452,000 | -4.0% | 562,339 | 0.0% | 0.61% | +17.8% |
| Q1 2021 | $2,553,000 | -24.3% | 562,339 | -4.3% | 0.52% | -24.9% |
| Q4 2020 | $3,371,000 | -59.8% | 587,339 | -49.3% | 0.69% | -58.5% |
| Q3 2020 | $8,393,000 | +4.6% | 1,159,236 | -49.6% | 1.66% | -29.0% |
| Q2 2020 | $8,027,000 | +3995.4% | 2,299,982 | +1636.2% | 2.34% | +3448.5% |
| Q1 2020 | $196,000 | -93.8% | 132,474 | -44.8% | 0.07% | -92.3% |
| Q1 2019 | $3,185,000 | +116.1% | 239,827 | +28.0% | 0.86% | +60.1% |
| Q4 2018 | $1,474,000 | +143.6% | 187,327 | +149.8% | 0.54% | +71.0% |
| Q3 2017 | $605,000 | -49.5% | 75,000 | -38.5% | 0.31% | -66.6% |
| Q4 2014 | $1,198,000 | – | 121,900 | – | 0.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |